NCT01722305 - Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2013

Primary Completion Date

June 3, 2016

Study Completion Date

July 15, 2019

Conditions

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt LymphomaCentral Nervous System LymphomaIntraocular LymphomaPrimary Diffuse Large B-Cell Lymphoma of the Central Nervous SystemRecurrent Adult Diffuse Large Cell LymphomaRetinal Lymphoma

Interventions

DRUG

Dexamethasone

Given PO

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

OTHER

Pharmacological Study

Optional correlative studies

DRUG

Pomalidomide

Given PO

Trial Locations (7)

10065

Memorial Sloan-Kettering Cancer Center, New York

22908

University of Virginia Cancer Center, Charlottesville

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

98109

Fred Hutchinson Cancer Research Center, Seattle

32224-9980

Mayo Clinic in Florida, Jacksonville

02115

Dana-Farber Harvard Cancer Center, Boston